SCHEMBL4889924

SCHEMBL4889924

CN1CCC(N(C)CC(O)C(O)(c2ccccc2)c2ccccc2)CC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.58
KMT2A Q03164 3/20 0.43
PKM P14618 1/20 0.43
ALDH1A1 P00352 3/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C19 P33261 1/20 0.42
HSD17B10 Q99714 1/20 0.42
CHRM3 P20309 3/20 0.41
CHRM2 P08172 1/20 0.41
CHRM4 P08173 1/20 0.41
CHRM5 P08912 1/20 0.41
CHRM1 P11229 1/20 0.41
MEN1 O00255 2/20 0.41
TTR P02766 1/20 0.41
HTR2A P28223 2/20 0.41
HTR2C P28335 2/20 0.41
PIM1 P11309 1/20 0.40
NOS3 P29474 1/20 0.38
NOS1 P29475 1/20 0.38
NOS2 P35228 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4889925 0.84 KDM4E (0.53) KDM4EKMT2AALDH1A1CYP2D6CHRM3
SCHEMBL4883043 0.76 CHRM3 (0.53) KDM4EKMT2APKMALDH1A1CHRM3
SCHEMBL4888039 0.73 CHRM3 (0.59) KDM4EALDH1A1CYP2D6CHRM3CHRM2
SCHEMBL17285985 0.72 KMT2A (0.55) KDM4EKMT2AALDH1A1CHRM3CHRM2
SCHEMBL4883173 0.72 GAA (0.58) KDM4EKMT2AALDH1A1CHRM3CHRM2
SCHEMBL8442356 0.69 KDM4E (0.68) KDM4EKMT2AALDH1A1HTR2AHTR2C
SCHEMBL2056178 0.67 GRIN2B (0.58) KDM4EKMT2APKMALDH1A1CYP2D6
SCHEMBL10147165 0.66 PIK3CD (0.57) KDM4EKMT2AALDH1A1HTR2AHTR2C
SCHEMBL12359041 0.66 KDM4E (0.49) KDM4EKMT2APKMALDH1A1CHRM3
SCHEMBL10293580 0.66 MAPT (0.49) KDM4EKMT2ACHRM3CHRM4CHRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1794161-A2 MUSCARINIC RECEPTOR ANTAGONISTS Ranbaxy Laboratories Limited (IN) 2007-06-13 EP claimed
WO-2006032994-A2 MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2006-03-30 WO claimed
US-20080280883-A1 Muscarinic Receptor Antagonists RANBAXY LABORATORIES LIMITED (IN) 2008-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280883-A1 Muscarinic Receptor Antagonists CHRM3, CHRM5, CHRM2 KDM4E 3801/4885KMT2A 2763/4885PKM 2144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.